Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Arch. endocrinol. metab. (Online) ; 63(4): 394-401, July-Aug. 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1019358

RESUMO

ABSTRACT Objective To measure type 1 serum amino-terminal propeptide procollagen (P1NP) and type 1 cross-linked C-terminal telopeptide collagen (CTX) before parathyroidectomy (PTX) in PHPT patients, correlating these measurements with bone mineral density (BMD) changes. Subjects and methods 31 primary hyperparathyroidism (HPTP) were followed from diagnosis up to 12-18 months after surgery. Serum levels of calcium, parathyroid hormone (PTH) vitamin D, CTX, P1NP, and BMD were measured before and 1 year after surgery. Results One year after PTX, the mean BMD increased by 8.6%, 5.5%, 5.5%, and 2.2% in the lumbar spine, femoral neck (FN), total hip (TH), and distal third of the nondominant radius (R33%), respectively. There was a significant correlation between BMD change 1 year after the PTX and CTX (L1-L4: r = 0.614, p < 0.0003; FN: r = 0.497, p < 0.0051; TH: r = 0.595, p < 0.0005; R33%: r = 0.364, p < 0.043) and P1NP (L1-L4: r = 0,687, p < 0,0001; FN: r = 0,533, p < 0,0024; TH: r = 0,642, p < 0,0001; R33%: r = 0,467, p < 0,0079) preoperative levels. The increase in 25(OH)D levels has no correlation with BMD increase (r = -0.135; p = 0.4816). On linear regression, a minimum preoperative CTX value of 0.331 ng/mL or P1NP of 37.9 ng/mL was associated with a minimum 4% increase in L1-L4 BMD. In TH, minimum preoperative values of 0.684 ng/mL for CTX and 76.0 ng/mL for P1NP were associated with a ≥ 4% increase in BMD. Conclusion PHPT patients presented a significant correlation between preoperative levels of turnover markers and BMD improvement 1 year after PTX.


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Fragmentos de Peptídeos/metabolismo , Peptídeos/metabolismo , Densidade Óssea , Paratireoidectomia/reabilitação , Pró-Colágeno/metabolismo , Colágeno Tipo I/metabolismo , Hiperparatireoidismo Primário/metabolismo , Hormônio Paratireóideo/sangue , Fragmentos de Peptídeos/sangue , Período Pós-Operatório , Vitamina D/sangue , Biomarcadores/sangue , Cálcio/sangue , Valor Preditivo dos Testes , Pró-Colágeno/sangue , Hiperparatireoidismo Primário/cirurgia
2.
Journal of Korean Medical Science ; : 653-658, 1999.
Artigo em Inglês | WPRIM | ID: wpr-83042

RESUMO

Previous studies have demonstrated that enalapril and verapamil seem to attenuate the cyclosporine nephrotoxicity. However, the mechanisms have not been completely understood, especially on molecular events. The aim of this study was to examine the effect of individual or combined treatment on osteopontin, TGF-beta, endothelin-1 and procollagen alpha 1(I) mRNA expressions. Enalapril (50 mg/L in drinking water) and verapamil (0.5 mg/kg/day, subcutaneously), alone or in combination, were administered to rats with chronic cyclosporine nephrotoxicity (cyclosporine, 25 mg/kg/day, subcutaneously) (n = 5 each). Five rats treated with olive oil vehicle were used as control. After 4 weeks, biochemical parameters were measured, and renal cortical mRNA levels were evaluated by Northern blot analysis. Cyclosporine reduced renal creatinine clearance significantly and induced renal cortical osteopontin, TGF-beta, endothelin-1 and procollagen alpha 1(I) gene expressions around 13.5 +/- 1.3, 2.4 +/- 0.2, 1.5 +/- 0.1, 1.9 +/- 0.1 folds, respectively. Individual treatment with enalapril or verapamil significantly suppressed the osteopontin and TGF-beta mRNA expression, but not endothelin-1 and procollagen alpha 1(I). Combined treatment also inhibited the osteopontin and TGF-beta mRNA expression but there was no difference between combined and individual treatment. In conclusion, enalapril or verapamil significantly blunted the cyclosporine-induced osteopontin and TGF-beta gene expressions. However, combined treatment did not show any additive effect.


Assuntos
Masculino , Ratos , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Animais , Bloqueadores dos Canais de Cálcio/uso terapêutico , Ciclosporina/efeitos adversos , Quimioterapia Combinada , Enalapril/uso terapêutico , Enalapril/administração & dosagem , Endotelina-1/metabolismo , Endotelina-1/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Imunossupressores/efeitos adversos , Córtex Renal/metabolismo , Nefrite/tratamento farmacológico , Nefrite/induzido quimicamente , Pró-Colágeno/metabolismo , Pró-Colágeno/genética , RNA Mensageiro/análise , Ratos Wistar , Sialoglicoproteínas/metabolismo , Sialoglicoproteínas/genética , Fator de Crescimento Transformador beta/metabolismo , Fator de Crescimento Transformador beta/genética , Verapamil/uso terapêutico , Verapamil/administração & dosagem
4.
Indian J Exp Biol ; 1989 May; 27(5): 472-3
Artigo em Inglês | IMSEAR | ID: sea-62148

RESUMO

Glutathione has been shown to inhibit trypsin induced proteolytic activity. A concentration of 6 mM of glutathione was found to completely inhibit proteolysis of 3H-proline labelled underhydroxylated procollagen as a substrate, whereas a concentration of 2.1 mM of glutathione caused 50% inhibition of proteolysis. When azocoll was used as a substrate for trypsin 50% inhibition of proteolysis was achieved with 1.4 mM of glutathione, though a complete proteolytic inhibition was attained at 4 mM glutathione. The results suggest that glutathione may be playing an important role in protein metabolism in a variety of disease and stress states.


Assuntos
Animais , Fibroblastos , Glutationa/farmacologia , Camundongos , Pró-Colágeno/metabolismo , Tripsina/metabolismo , Inibidores da Tripsina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA